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Non-vitamin K antagonist oral anticoagulants (NOACs) are increasingly used for the prevention and treatment of
venous thromboembolism and for stroke prevention in patients with atrial fibrillation. NOACs do not require routine
coagulation monitoring, creating a challenge to established systems for patient follow-up based on regular blood
tests. Healthcare professionals (HCPs) are required to cope with a mixture of patients receiving either a vitamin K
antagonist or a NOAC for the same indications, and both professionals and patients require education about the
newer drugs. A European working group convened to consider the challenges facing HCPs and healthcare systems
in different countries and the educational gaps that hinder optimal patient management. Group members emphasised
the need for regular follow-up and noted national, regional and local variations in set-up and resources for follow-up.
Practical incorporation of NOACs into healthcare systems must adapt to these differences, and practical follow-up that
works in some systems may not be able to be implemented in others. The initial prescriber of a NOAC should
preferably be a true anticoagulation specialist, who can provide initial patient education and coordinate the
follow-up. The long-term follow-up care of patients can be managed through specialist coagulation nurses, in a
dedicated anticoagulation clinic or by general practitioners trained in NOAC use. The initial prescriber should be
involved in educating those who perform the follow-up. Specialist nurses require access to tools, potentially including
specific software, to guide systematic patient assessment and workflow. Problem cases should be referred for
specialist advice, whereas in cases for which minimal specialist attention is required, the general practitioner could
take responsibility for patient follow-up. Hospital departments and anticoagulation clinics should proactively engage
with all downstream HCPs (including pharmacists) to ensure their participation in patient management and
reinforcement of patient education at every opportunity. Ideally, (transmural) protocols for emergency situations
should be developed. Last but not least, patients should be well-informed about their condition, the treatment,
possible risk scenarios, including the consequences of non-adherence to prescribed therapy, and the organisation
of follow-up care.
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anticoagulants and the need for education
The well-documented limitations of vitamin K antagonists
(VKAs) have led to the development of non-VKA oral an-
ticoagulants (NOACs) that have more predictable pharma-
cological properties, do not require routine coagulation
monitoring, depend less on patient and lifestyle factors,
and have fewer restrictions in terms of diet and
co-medications [1]. NOACs are changing clinical practice
and are increasingly used for the prevention and treatment
of venous thromboembolism (VTE) and stroke prevention
in patients with non-valvular atrial fibrillation (AF).
Unlike VKAs, NOACs are not subject to regular dose
adjustments [2]; however, their use requires changes to
established systems for patient follow-up based on regular
blood tests. The lack of a need for regular coagulation
monitoring should not preclude regular contact with
healthcare professionals (HCPs) to oversee the safe and
effective management of NOAC therapy. Important checks
include monitoring of renal and hepatic function, exclusion
of thrombocytopenia or anaemia (especially in elderly
patients), assessment of nuisance bleeding or other adverse
events, confirmation of adherence to the prescribed medi-
cation and evaluation of other aspects of overall treatment
and health, including optimal management of hypertension
[2]. Because some patients are well managed on VKAs or
have conditions for which NOACs are contraindicated (e.g.
prosthetic heart valves), HCPs and healthcare systems are
increasingly required to cope with patients receiving either
a VKA or a NOAC for the same or different indications.
Anecdotal evidence suggests that many HCPs lack
education on NOACs and are concerned about pre-
scribing them. Additionally, specific management and
follow-up protocols (e.g. for serious bleeding compli-
cations) are still in development. Although some
patients receiving NOACs may not require frequent
contact with an HCP, others, such as those with
co-morbid conditions, renal impairment or a high risk
of bleeding complications, should be seen more often.
HCPs and patients must understand relevant aspects
of the prescribed anticoagulant and the important
differences between NOACs and VKAs. In many (but
not all) countries, monitoring of patients receiving
VKAs is usually performed at a dedicated outpatient
clinic [3], and staff at these clinics serve well as focal
disseminators of education on NOACs to HCPs and
patients.
This document has been created to consider best
practice for dissemination of education and the evolv-
ing role of the coagulation clinic in the NOAC era.
Development of this document
A workshop was held in September 2013 involving
European HCPs with expertise in anticoagulation froma range of specialties, including cardiologists, haematol-
ogists and specialist nurses from Belgium, Finland, Italy,
Portugal, Slovenia, Spain and the United Kingdom. This
working group was asked to consider the challenges
facing HCPs and healthcare systems in their countries
with respect to the introduction of NOACs, and the
gaps in educational structures and settings that hinder
or endanger the optimal management of patients receiv-
ing these drugs. The outputs of the discussions were
taken forward to create this manuscript. Bayer Health-
Care provided logistical support for the meeting.Current models of anticoagulant prescription and
monitoring
To understand the flow of educational information
within an anticoagulation management paradigm, it is
first necessary to consider commonly used patient man-
agement models. These models are built primarily for
patients receiving long-term VKA therapy and fall into
two main categories: anticoagulation clinic coordination
and coordination by general practitioners (GPs). In some
systems, a hybrid model exists, in which unstable or
complicated patients are seen in a hospital clinic and
stable patients are managed by their GP. In all cases, the
networking between these functions is critically
important.Anticoagulation clinic model
Patients regularly attend a specialist outpatient clinic for
international normalised ratio (INR) monitoring. Follow-
ing prespecified algorithms, a nurse may take responsi-
bility for INR interpretation and subsequent VKA dose
adjustment, or may refer to the supervising consultant
cardiologist or haematologist for atypical patients or
scenarios. The nurse or consultant (or both) may take
responsibility for educating the patient on their condition
and treatment. Official anticoagulation clinics exist in
several European countries, including Belgium, Italy,
the Netherlands, Portugal, Spain, Slovenia, Sweden and
the United Kingdom, but in many countries this service is
decentralised.General practitioner model
In the absence of a dedicated outpatient clinic, responsi-
bility for ongoing monitoring of patients receiving
chronic anticoagulant therapy generally falls to GPs. GPs
tend to be familiar with VKAs and have a detailed know-
ledge of their patients’ health and lifestyle. Practice
nurses may take responsibility for routine INR monitor-
ing in some cases. The GP model is used in Germany
and to a variable extent in other countries. The risk of
non-uniform management strategies and the lack of
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ptrecent study in the United States reported that the
number of patients tested per GP practice was posi-
tively associated with INR time in therapeutic range
(TTR) [4].Possible new models for long-term non-vitamin K
antagonist oral anticoagulant care
Current systems face the need to integrate patients tak-
ing NOACs with those taking VKAs. Consultant cardi-
ologists and haematologists have a strong knowledge
base to support this integration but may not be at the
front line of day-to-day patient interaction. Therefore, it
is important that their knowledge is disseminated to
nurses, GPs and other relevant HCPs. The models pre-
sented here draw on previous work by members of this
consensus group [5]. Each model has advantages and
drawbacks (Table 1) and would require adaptation to ac-
count for specific differences in country, regional and
local healthcare systems.Table 1 Advantages, disadvantages and requirements of propo
K antagonist oral anticoagulants or vitamin K antagonists
Model Initial
prescriber
HCP
responsible
for routine
follow-up
Advantages
Nurse-
coordinated
anticoagulation
clinic
Hospital
specialist
Nurse specialist • Nurses well placed to coor
contact with patients, the
prescriber and other HCPs
• Nurses can take a holistic v
(co-morbidities), make a fu
assessment and educate th
patient
• Less intensive for the spec
allowing them to focus ful
the treatment plan
Nurse-assisted
anticoagulation
clinic
Hospital
specialist
Cardiologist/
haematologist,
assisted by
nurse
• Nurse does not require ext
anticoagulation expertise b
still organise patient visits
provide basic checks and
education
GP coordinated,
without
anticoagulation
clinic
Hospital
specialist or
specialist GP
GP • Reduces pressure on hospi
resources
• GPs generally know their p
well
• Can perform home visits
GP, general practitioner; HCP, healthcare professional; NOAC, non-vitamin K antagoAnticoagulation clinic models
Nurse coordinated
Specialist anticoagulation nurses are well placed to
drive the integration of NOACs into existing anticoa-
gulation clinic structures [5]. In the nurse-coordinated
model, a nurse coordinator, working according to
standard operating procedures, takes responsibility for
routine patient management in the anticoagulation
clinic. The clinic is largely autonomous but remains
under the supervision of consultant physicians, who
see patients at predefined intervals and/or on referral
from the nurse. The nurse keeps in contact with the
patient, determines the frequency of clinic visits and
may provide education to GPs, pharmacists and patients
and their families about the medical condition and its
treatment (Figure 1). Sufficient resources for training ex-
pert nurses and mechanisms for benchmarking and qual-
ity control are required. Pressure on resources could be
eased by identifying easy-to-manage, low-risk patients re-
ceiving NOACs, with whom contact could be maintained
primarily through the GP, with the nurse coordinatorsed models for monitoring of patients taking non-vitamin
Disadvantages Requirements for NOAC
integration
dinate
initial
• Requires well-
educated expert
nurses and resources
for an anticoagulation
clinic
• Determination of individual patient
visit schedules
iew
ll
e • Medico-legal liability
issues
• Easy-to-manage patients could
have primary contact through
the GP; clinic could function as a
coordinator and remote evaluator
of care
ialist,
ly on
• Non-medical as well as medical
aspects and patient preference to
be taken into account when
considering whether to switch from
VKA to NOAC
ensive
ut can
and
• Resource- and time-
heavy for specialist
• As above
tal • Increased pressure on
GP resources
• GPs to maintain contact with
patients at a frequency based on
patient risks and preferences
atients • GPs must be well
trained in
anticoagulation (NOACs
as well as VKAs)
• Specialist department to be
available to evaluate the patient at
the GP’s request
• Good relationship/
network needed
between hospital
departments and local
community physicians
• GP may rely on the specialist for
his/her own education – only
well-educated GPs should be
prescribers of NOACs
nist oral anticoagulant; VKA, vitamin K antagonist.
Figure 1 Patient flow and educational pathways in a model of long-term management of patients receiving NOACs. AF, atrial fibrillation; GP,
general practitioner; HCP, healthcare professional; NOAC, non-vitamin K antagonist oral anticoagulant; VTE, venous thromboembolism.
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up (e.g. by telephone with the patient or GP). In this case,
the clinic functions as a structured coordinator of care,
even when it is delivered by others.
Nurse assisted
The cardiologist/haematologist at the anticoagulation
clinic may be the primary care coordinator [5] who
manages the workflow and be the point of contact for
the patient (Figure 1). This system requires a lower level
of nurse expertise, although nurses can still assume
much of the daily organisation and patient education.
On the other hand, this model is time- and resource-
heavy for the responsible physicians. Anticoagulation
clinics in Italy, and some in Spain, use this system.
General practitioner model
In systems lacking dedicated anticoagulation clinics, the
GP is responsible for routine follow-up of patients taking
NOACs (Figure 1). The GP can refer to the hospital con-
sultant in the event of problems that require specialist
intervention, such as a thromboembolic event or major
bleeding episode. GP-based follow-up can ease the
demands on hospital resources, and the GP may even
perform home visits for elderly patients or others for
whom office visits are difficult. Many GPs are currently
undereducated about NOAC therapy and may consider
that the lack of routine coagulation monitoring meansthat no follow-up is needed, or may be unwilling to allo-
cate time and resources to educate and evaluate patients
receiving NOACs. A good relationship and networking
opportunities between cardiology/haematology depart-
ments and GPs is, therefore, vital.
GPs should maintain contact with their patients at a
frequency advised by the initial prescriber based on the
patient’s risk profile and preferences. The GP may rely
on the hospital cardiology/haematology department for
their own education on NOAC therapy. In some coun-
tries (such as Belgium, Finland, Germany, Portugal and
Spain), GPs are allowed to initiate anticoagulant treat-
ment. This may not be ideal unless they have specialist
knowledge of NOACs, but even so, the mechanisms for
quality control remain uncertain.
Important considerations for incorporation of non-
vitamin K antagonist oral anticoagulants into all models
Patients receiving NOACs may not need to interact with
an HCP as often as those taking VKAs, but nevertheless,
contact frequency should be based on individual medical
needs. Extensive contact may not be required for the
majority of patients who are in generally good health,
have a limited potential for relevant drug interactions
and have a low or moderate risk of bleeding, provided
that they receive appropriate education and are expected
or known to have good treatment adherence. In patients
with a high risk of bleeding, anaemia, thrombocytopenia
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suspected suboptimal adherence, the responsible HCP
should see the patient directly on a regular basis [6]. To
keep track of relevant information and remind patients
of important aspects of their therapy, the European
Heart Rhythm Association (EHRA) has proposed a
universal NOAC patient anticoagulation card (Figure 2;
printable version in supplementary material) [2], and
companies have produced drug-specific versions
(example in Figure 3). Information on the patient’s base-
line (non-anticoagulated) readings for relevant genericFigure 2 Adapted European Heart Rhythm Association (EHRA) proposal fo
antagonist oral anticoagulants. Pharmacy has been included in the list of v
anticoagulation) generic coagulation assays and the date of the test have b
printable version of this card is available as a supplementary file. Adapted f
practitioner; CrCl, creatinine clearance; NOAC, non-vitamin K antagonist oraor specific coagulation assays (e.g. activated partial
thromboplastin time or dilute thrombin time [Hemoclot®]
for dabigatran, and prothrombin time or anti-Factor Xa
assays for direct Factor Xa inhibitors), and the date on
which these tests were performed, could also be added to
the card or the electronic laboratory file of the patient.
This is important if these tests are used to check for the
presence or absence of a NOAC effect in an emergency.
For stable patients with AF receiving VKAs, the
European Society of Cardiology (ESC) considers a TTR of
70% to constitute good management [7]. However, in realr a universal anticoagulation card for patients receiving non-vitamin K
isit sites (page 2), and the results of baseline (prior to initiating
een added to the emergency information (page 4), as indicated. A
rom Heidbuchel et al. Europace 2013;15:625–51 [2]. GP, general
l anticoagulant.
Figure 3 Example of a drug-specific patient anticoagulation card for rivaroxaban. Copyright Bayer HealthCare, reproduced with permission.
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and in some randomised clinical studies in which the
INR was monitored rigorously, the mean TTR was only
55–65% [10-13]. HCPs should consider whether their
patient really is well managed on a VKA; considering the
broad indications for NOAC therapy, it is likely that most
patients are candidates for switching to NOACs, provided
they do not have contraindications. For a patient with
poor adherence, the HCP responsible may feel more com-
fortable with regular monitoring, but constant dose ad-
justments due to irregular INRs may actually contribute
to the problem, and switching to a fixed-dose NOAC may
simplify treatment and improve adherence. The possible
psychological impact on patients caused by the loss of
monitoring visits (e.g. social contact for elderly patients
and reassurance that their medication is working) may be
overcome by regular visits for other necessary tests or an
overall health check. However, the decision to switch or
not should be taken by the HCP and the patient in tan-
dem, based on both being informed about the treatment
choices available.
To harmonise procedures, a centralised database of all
NOAC- and VKA-anticoagulated patients should becreated and made available to all relevant HCPs within
the local system. This database should provide informa-
tion on diagnosis, drug and dose regimen and anticipated
duration of treatment, alongside agreed standard manage-
ment protocols. Data on INR measurements and TTR
would also be useful to inform decisions about switching.
The information within such a system could be controlled
by the relevant overseeing specialist department.
Opinion statements
 Where the healthcare structure allows, long-term
management of patients receiving anticoagulation
can be efficiently handled by a centralised
(anticoagulation) clinic. As an alternative, GPs or
specialist nurses with appropriate training and
experience can take responsibility, with specialist
support and supervision
 Initiation of NOAC treatment should be restricted
to GPs who receive specialist training and should
otherwise be avoided
 Practical incorporation of NOACs into healthcare
systems must take into account national, regional
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resources; anticoagulation clinics may be best suited
to handle routine medical and educational tasks and
networking between specialties
 Problem cases and scenarios need to be referred to
an expert facility run by coagulation specialists
Flow of education to support non-vitamin K antagonist
oral anticoagulant implementation: needs, responsibilities
and support materials
Patients receiving anticoagulants have contact with dif-
ferent HCPs (including, but not limited to, those speci-
fied in this document) at different time points during
their treatment. Each of these HCPs has a responsibility
to educate and/or reinforce patient education. HCPs
must have the appropriate level of knowledge and be
able to communicate it effectively in terms that the
patient can understand. This requires that information
migrates from clinical consultants (usually the initial
prescribers) through the layers of the healthcare network
to reach the patient. This can occur through regular
HCP education meetings in the anticoagulation clinic,
adoption of national guidelines, support from patient
anticoagulation associations and provision of public
information.
The initial prescriber
The clinical diagnosis of a thromboembolic condition
and the initial decision to prescribe anticoagulant treat-
ment is best done by a specialist (e.g. a cardiologist,
neurologist, geriatrician or haematologist) rather than by
a GP or other physician without training or experience
of anticoagulant treatment. Firstly, specialists have ac-
cess to the latest clinical data and insights and, therefore,
have the expertise to make the initial prescribing deci-
sion (and plan the length of treatment); secondly, they
can provide patient education and disseminate relevant
information to other HCPs involved in downstream care
(Table 2, Figure 1); and thirdly, they also gather centra-
lised data on complications and their management,
which are useful for the wider healthcare community.
Ideally, education should be based on national guidelines
written by representatives of those disciplines that are
most likely to encounter emergency situations involving
NOACs.
After discharge, the initial prescriber often ceases to
have primary responsibility for patient follow-up but
should remain available to consult in the case of difficul-
ties. The responsible HCP should be aware of the sce-
narios, such as trauma and acute inflammatory and
gastrointestinal diseases (poor absorption or vomiting),
that should trigger a specialist consultation. In countries
such as Italy, the initial prescriber, in most cases the
haematologist working in the anticoagulation clinic, isalso responsible for follow-up of patients receiving
NOACs.
Many cases of VTE or AF are diagnosed in the emer-
gency room. Patients entering the system via this route
may never actually be admitted to an inpatient depart-
ment, but instead may be discharged with a prescription
for an oral anticoagulant. It would be preferable for
these patients to transition first via an anticoagulation
clinic.
Opinion statements
 The initial prescriber should preferably be an
experienced specialist
 The initial prescriber is also responsible for initial
patient education and for educating other HCPs
about thrombotic conditions, anticoagulant
treatment and duration, and risk scenarios
 The initial prescriber may or may not have primary
responsibility for further follow-up, but should be
available for consultation and to gather information
on complications
Anticoagulation clinic nurse
It is the opinion of this writing group that the follow-up
and continuing education of all patients receiving long-
term NOAC or VKA anticoagulation in the community
is best performed by a specialist anticoagulation clinic,
headed either by a specialist nurse(s) (nurse coordinated)
or by a cardiologist/haematologist supported by nurses
(nurse assisted). In the NOAC era, in patients treated
for VTE, an ideal time for a first follow-up visit may be
at the point that patients transition from parenteral to
dabigatran therapy or from the more intensive doses of
apixaban (after 7 days of treatment) or rivaroxaban (after
21 days). During follow-up, the role of the anticoagula-
tion nurse becomes wider than basic INR monitoring
and includes other tests, such as calculating creatinine
clearance, taking a holistic view of patient care and pro-
viding education to patients and other HCPs (Table 2,
Figure 1). This education includes knowledge about un-
stable situations, such as acute illness, starting or stop-
ping co-medications, trauma and management of major
and even minor (e.g. tooth extraction) surgery. A single
clinic is likely to be responsible for patients receiving
NOACs and those receiving VKAs and must address the
different requirements of all patients.
Evidence suggests that patients with AF have a poor
level of education about their disease, its severity and its
treatment [14], and that improving their knowledge is
crucial to the success of anticoagulant therapy [15,16].
The University of Maastricht in the Netherlands has pio-
neered a software-based approach to nurse-led coordin-
ation of care. Patient data are entered into the software
Table 2 Educational needs and responsibilities for healthcare professionals responsible for patients receiving non-vitamin K antagonist oral anticoagulant therapy
The initial prescriber The anticoagulation clinic nurse The general practitioner The pharmacist The patient
Needs Needs Educational needs Educational needs Educational needs
• Access to the latest data and expert
opinion via colleagues, academic
literature, and internal and external
meetings and congresses
• To receive regular updates on
current best practice from the
cardiology/haematology
department (as detailed above);
nurse coordinators also need
access to academic literature and
the chance to attend national
coagulation nursing meetings
• Ongoing updates (6-monthly in the
first 1.5 years and annual thereafter)
from specialists on evolving
treatment options for VTE/AF; these
could be provided online or by
email, or via an in-hospital training
day, and tied to professional
development
• Ongoing (annual or ad hoc)
updates from anticoagulation clinic
nurses and/or GPs regarding the
loco-regional organisation of
structured anticoagulant care
(who is responsible for what, which
lines of communication are available,
etc.) and questions to ask the patient
when filling a prescription
(adherence – check blister pack)
• Basic knowledge of their
condition, treatment and the
importance of adherence
• Simple flowcharts outlining
recommended indications,
dose adjustment and
follow-up
• Clear and concise guides on how
to perform follow-up actions
(SOPs), including clear instructions
on how and when to contact their
supervising physician, GPs, other
HCPs and patients themselves
throughout follow-up
– GPs are likely to be familiar with
VKAs but less so with NOACs,
and they will need to receive
education on the differences
between NOACs and other
agents, and important aspects
of ongoing care of patients
receiving NOACs, including
patient education
Educational responsibilities
• Awareness of what to do if an
adverse event occurs, and
ability to differentiate between
minor and major events
Responsibilities
• Software to assist in these tasks
– What to do in different scenarios;
what constitutes an emergency/
which issues should be referred
via a routine appointment to the
coagulation clinic/specialist
department
• To patients:
• Regular contact with an HCP
responsible for follow-up at a
frequency dependent on
individual risk assessment
• Provide education to other hospital
departments and community GPs
on treatment options for VTE/AF
(regular updates)
• To the patient (at each visit)
– Support with posters/checklists/
desk note reminder cards,
references to online sources of
information
– Ensure that appropriate
questions are asked of the
patient when they collect their
medication, based on the
indication for use and the type
of patient (elderly, with renal
impairment, etc.) and
medication (NOAC, VKA, etc.)
• Materials and tools to assist
with ongoing education and
therapeutic adherence– Hospital meetings, including
specific training days for GPs if
practicable (could link to
professional development) Responsibilities
– Provide patient leaflets and
checklists to GP offices
– Ensure that patients are not
prescribed contraindicated
co-medications
Educational responsibilities
– Support with posters, checklists,
desk note reminder cards that
HCPs can take away and use;
provide links to online sources
of information
– Continual reinforcement of key
educational messages about the
anticoagulant they are taking
(NOAC or VKA) at each visit
(frequency of visits different for
each patient based on health
and risk factors for thrombosis/
bleeding as discussed above)
Educational responsibilities
– Add follow-up information to
the patient’s NOAC card
• To take a proactive role in their
own treatment
• Provide education and training to
anticoagulation clinic nurses (at least
6-monthly updates)
– Informal assessment of patient
understanding (e.g. can they
name their condition and explain
why they have to take an
anticoagulant, what the dose is,
what signs of bleeding they
should be looking out for, etc.?)
• To the patient
• Notify the coagulation clinic and/or
GP of any concerns about the
patient
– This could take the format of a
session co-chaired by a senior
nurse from the clinic or a GP
experienced in NOAC use plus
the specialist to give two different
perspectives (practical and
scientific)
– Support with printed leaflets
and checklists, educational
posters in the office, etc.
– In the absence of an
anticoagulation clinic: follow-up
with patients receiving
anticoagulants (NOACs or other)
at regular intervals (frequency
dependent on risk) to remind
them of the important aspects of
their medication and what to do
if they are concerned about an
aspect of their health relating to
their treatment
– Topics
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Table 2 Educational needs and responsibilities for healthcare professionals responsible for patients receiving non-vitamin K antagonist oral anticoagulant therapy
(Continued)
• To GPs – As an adjunct to an
anticoagulation clinic: take the
opportunity at any patient visit
for any reason other than
anticoagulation to remind them
of the important points
regarding their anticoagulant
treatment (adherence – check
blister pack to make sure all
doses taken)
• Which patients are suitable for
NOACs (e.g. stable condition,
good renal function,
knowledgeable about treatment,
having a carer in charge of
medication) vs which are not
(or less) suitable (e.g. confused,
elderly, likely to be non-
compliant, with contraindications)
– support with case studies
– Periodical (3- to 6-monthly?)
contact to check on individual
patients
• To pharmacists (ad hoc
communication):
• Fundamental aspects of each
NOAC vs heparin/VKAs (e.g.
predictable pharmacology,
drug interactions, etc.)
• Those requiring only infrequent
visits to the anticoagulation
clinic
– Pass on educational information
on questions to ask the patient
before issuing a repeat
prescription (this interaction
could be mediated by the
patient NOAC card)
• Practical guides (e.g. based on
EHRA advice) on topics such as
taking a full bleeding history,
calculating risk score
(CHA2DS2-VASc, HAS-BLED,
etc.),
switching, appropriate
laboratory tests and how to
interpret them
• Follow-up on patients who
have missed scheduled clinic
visits
– Remind about important
aspects of pharmacology, drug
interactions, etc.
• ‘What to do if…’ guidance,
including identification of
potential emergency scenarios
(serious bleeding event, e.g.
head injury, major surgery
required) vs minor problems
(e.g. nose bleed, minor
surgical procedure) and
whom to contact in each case
• Receive information on
changes of patient status that
may lead to an intensification
of follow-up (e.g. anaemia,
thrombocytopenia, new con-
comitant medication that may
increase the risk of bleeding,
exclusion of hypertension)
– Send posters/checklists;
encourage pharmacist to get in
contact if they have concerns
• Latest information on patient
adherence and how it can be
improved; which practical
tools they can use and offer
to patients
– Reminders about key aspects of
anticoagulants (NOAC and VKA),
e.g. pharmacology, drug
interactions, etc., and warning
signs to look out for in patients
receiving them (e.g. bleeding,
vomiting, bruising)
– Smartphone/tablet apps and
other online tools could be
used in case physical meetings
cannot be held
– Support with posters/checklists/
desk note reminder cards,
references to online sources of
information
• Education of the patient about
their condition and how it will be
managed
• To the pharmacist
– First discussion at point of initial
prescription
– Periodical (annual?) contact to
remind pharmacists about
questions they should ask the
patient when filling a repeat
prescription for any
anticoagulant (e.g. ask the
patient to present his/her NOAC
card; the pharmacist could also
complete a line on the follow-up
page of the NOAC card,
indicating how many drug doses
have been delivered or any other
important information), and,
specifically for NOAC vs LMWH/
VKA, whom to contact in case of
concerns
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(Continued)
• Emphasise patient
understanding of their
condition and the drug they
are taking (NOAC or VKA), and
the importance of correct
adherence to the prescribed
regimen – use language that
the patient can understand
– Key information on
pharmacology and drug
interactions
• Support with printed leaflets
and checklists that the patient
can take home – these can
include QR codes/online links,
but should be physical copies
so that patients can keep
them in a convenient place
and have constant access
to them
– Support with posters/checklists/
desk note reminder cards,
references to online sources of
information
– Second discussion to reinforce
messages before discharge
• Warning signs to look out for
(e.g. anaemia,
thrombocytopenia,
hypertension, bleeding,
vomiting, bruising)
• Importance of keeping
follow-up appointments with
coagulation clinic/GP
• Why adherence is important
– Support with printed leaflets and
checklists as above
– Provision of NOAC card to the
patient
AF, atrial fibrillation; EHRA, European Heart Rhythm Association; GP, general practitioner; LMWH, low molecular weight heparin; NOAC, non-vitamin K antagonist oral anticoagulant; QR, quick response; SOP, standard
operating procedure; VKA, vitamin K antagonist; VTE, venous thromboembolism.
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Figure 4 Basic educational checklist for healthcare professionals when managing patients starting non-vitamin K antagonist oral anticoagulant
therapy. NOAC, non-vitamin K antagonist oral anticoagulant; VKA, vitamin K antagonist.
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of therapy, based on guidelines. The nurse-led approach,
overseen by a supervising cardiologist, was shown to re-
duce cardiovascular hospitalisations and deaths [17], and
to correlate with an improvement in patients’ AF-related
knowledge over time [18], compared with standard
cardiologist-led care. Centres could consider developing
their own software or adapting existing programs to fit
their protocols. A sample checklist for patient education
is shown in Figure 4. Materials such as booklets, vali-
dated websites, smartphone apps and short videos that
provide important information to patients in an access-
ible manner are extremely useful.Opinion statements
 A specialist coagulation nurse is well placed to
take overall responsibility for patient education
and to coordinate follow-up with other HCPs
 Coagulation nurses require specialist education,
examples of best practice, and access to simple
and effective tools to assist with patient
education
 Specific software tools that help the nurse with
systematic assessment of the patient and
workflow guidance should be developed and
shared
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A GP is often involved in the initial diagnosis of a thrombo-
embolic disorder but should be encouraged to swiftly refer
all suspected cases to the specialist hospital department.
This is especially important in patients with suspected pul-
monary embolism and those with renal or hepatic impair-
ment. It is possible that GPs consider they have a
responsibility to prescribe anticoagulation therapy. How-
ever, if an established care network with rapid back-up from
a specialist centre is available, they may be more willing to
refer the prescribing decision to a specialist, which will im-
prove overall patient care.
The GP may be the most frequent point of contact for a
patient receiving a NOAC after discharge and can take re-
sponsibility for follow-up of patients deemed at low risk.
In the absence of an anticoagulation clinic, the role of GPs
in patient education assumes greater importance and they
will have the main responsibility for long-term patient
follow-up (Table 2, Figure 1). Hospital departments and
anticoagulation clinics should proactively engage with GPs
and provide them with education and training on the
management of patients taking NOACs.
A GP education programme for NOACs should have a
practical focus and include obligatory training sessions
with real-life problems/clinical cases that the GPs can
submit for discussion, as well as simple guidance and algo-
rithms. GPs should know whom to contact in the specialist
centre in case of questions or concerns about specific
patients.Opinion statements
 In the absence of an anticoagulation clinic, GPs
are likely to take responsibility for the
management and ongoing education of patients
receiving NOACs
 Even when a clinic exists, patients considered at low
risk of bleeding may not be required to attend
regularly; in this case, the GP may take responsibility
for follow-up
 GPs should reinforce educational messages
regarding anticoagulation with patients at every
opportunity, even if the patient is visiting for
another reason
 Hospital departments or anticoagulation clinics
should proactively engage with GPs and provide
them with education on NOACsThe pharmacist
Pharmacists have an important (and so far underestimated
and underused) role in the monitoring of patient adher-
ence to NOAC treatment. In particular, they can checkthat patients understand the dose and regimen, as well
as reinforcing general educational messages (Table 2,
Figure 1). Hospital departments or anticoagulation clinics
should proactively engage with pharmacists to ensure they
can effectively participate in the management of patients
receiving anticoagulants. Some countries have national
databases that support the pharmacist in evaluating
patient adherence. Further research into the development
of such systems is warranted.
Opinion statements
 Pharmacists are important in checking patient
adherence
 Hospital departments or anticoagulation clinics
should proactively engage with pharmacists and
provide them with education on NOACs, including
drug interactions
The patient
In the NOAC era, with less regimented HCP contact,
patients must increasingly take responsibility for their
own understanding of their condition and treatment.
Primarily, they need to have a basic knowledge of why
they are being treated, how their treatment works, the
importance of adherence and what to do if an adverse
event occurs. Differentiation between a minor event
that can be self-managed (e.g. a nose bleed) and one that
should prompt them to contact an HCP or go to the
emergency department is required. Even if a patient is
not regularly attending a GP or anticoagulation clinic,
the responsible HCP should keep in regular contact, e.g.
with a brief telephone call. Patients should be able to ask
questions, and family members should be included if ap-
propriate, such as in the case of patients with diminished
self-responsibility. Materials can be provided to remind
patients of important information, and these should be
tailored to the individual patient. For example, a calen-
dar can help to remind patients to take their treatment,
but some patients may find a pill box with days of the
week, or a reminder on their mobile telephone, to be
more effective. Several organisations also offer online
patient support websites, including the EHRA (http://
www.afibmatters.org/), the AF Association in the UK
(http://www.atrialfibrillation.org.uk/) and Anticoagula-
tion Europe (http://www.anticoagulationeurope.org/).
Ideally, some of this content could be translated into
local languages. Patients must be aware of the import-
ance of their patient card (Figure 2).
Opinion statements
 Therapy is likely to be enhanced by proactively
involving the patient in the management of their
Heidbuchel et al. Thrombosis Journal  (2015) 13:22 Page 13 of 14condition; this requires that the appropriate level of
information is given using appropriate language, and
confirmation that the provided information has been
understood by the patient
 Educational messages should be reinforced with all
patients by all HCPs at every opportunity
Conclusions
Incorporation of NOACs into healthcare systems must
take account of national, regional and local variations,
and it is recognised that some systems may not be able
to incorporate all the suggestions in this document. The
initial prescriber of a NOAC should preferably be a spe-
cialist, who may handle problem and emergency cases as
well as proactively engage with all downstream HCPs to
ensure that they participate effectively in patient man-
agement and reinforce patient education. The initial pre-
scriber has to consider involvement in the education
of other HCPs and coordination of patient follow-up.
The long-term care of patients may be managed through
an anticoagulation clinic and/or specialist nurses, under
guidance and supervision. Coordination by GPs who
are trained in NOAC use is an alternative. GPs and
pharmacists should be involved in the follow-up path-
ways that are coordinated by anticoagulation clinics or
specialists. Last but not least, the patient should be well
informed about their condition, treatment, possible risk
situations and the organisation of follow-up care. Only a
patient with insight into their condition will be fully
adherent to therapy and follow-up and have a successful
outcome.
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